Central Pharmaceutical Joint Stock Company No3 (DP3) Q2 2025 earnings summary

Executive summary

• Net revenue for Q2/2025 reached VND 94.24 billion, down from VND 102.43 billion in Q2/2024; net profit after tax was VND 32.10 billion, up from VND 27.73 billion year-over-year.

• Six-month net revenue was VND 186.15 billion, a decrease from VND 206.09 billion in the same period last year.

• Net cash from operating activities for H1/2025 was VND 80.87 billion, a significant increase from VND 21.55 billion in H1/2024.

Financial highlights

• Gross profit for Q2/2025 was VND 32.20 billion, compared to VND 34.32 billion in Q2/2024.

• Operating profit for Q2/2025 was VND 41.14 billion, up from VND 35.39 billion year-over-year.

• Net profit after tax for H1/2025 was VND 55.96 billion, up from VND 49.77 billion in H1/2024.

• Basic EPS for Q2/2025 was VND 1,493, compared to VND 1,290 in Q2/2024.

• Total assets as of 30/06/2025 were VND 681.61 billion, up from VND 607.78 billion at the start of the year.

Segment performance

• Revenue from finished goods, merchandise, and services for H1/2025 was VND 190.70 billion, down from VND 207.79 billion year-over-year.

• Cost of goods sold for H1/2025 was VND 63.24 billion, compared to VND 67.25 billion in H1/2024.